{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:53:27Z","timestamp":1781600007845,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"DOI":"10.7759\/cureus.110942","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:10:51Z","timestamp":1781597451000},"source":"Crossref","is-referenced-by-count":0,"title":["Exceptional Long-Term Disease Stability Under Nivolumab in Recurrent High-Grade Glioma: A Case Report"],"prefix":"10.7759","author":[{"given":"Joana N","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca S","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Guilherme","family":"Gon\u00e7alves-Nobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe Soares","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012, 366:2443-54. 10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon DA","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, et al.. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6:1003-10. 10.1001\/jamaoncol.2020.1024","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis DN","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, et al.. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109. 10.1007\/s00401-007-0243-4","journal-title":"Acta Neuropathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al.. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016, 131:803-20. 10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al.. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021, 23:1231-51. 10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao J","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, et al.. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019, 25:462-9. 10.1038\/s41591-019-0349-y","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5681","article-title":"Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma","volume":"12","author":"Decraene B","year":"2023","unstructured":"Decraene B, Vanmechelen M, Clement P, et al.. Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma. Cancer Med. 2023, 12:11107-26. 10.1002\/cam4.5681","journal-title":"Cancer Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim M","year":"2018","unstructured":"Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018, 15:422-42. 10.1038\/s41571-018-0003-5","journal-title":"Nat Rev Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi ME","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, et al.. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352:997-1003. 10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3171\/CASE24539","article-title":"Long-term survival in a patient with Li-Fraumeni syndrome-associated giant cell glioblastoma treated with nivolumab: illustrative case","volume":"8","author":"Mitchell M","year":"2024","unstructured":"Mitchell M, Restrepo-Orozco A, Verhey LH, Vitaz T. Long-term survival in a patient with Li-Fraumeni syndrome-associated giant cell glioblastoma treated with nivolumab: illustrative case. J Neurosurg Case Lessons. 2024, 8:10.3171\/CASE24539","journal-title":"J Neurosurg Case Lessons"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221100863","article-title":"Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome-associated glioma","volume":"14","author":"Cabezas-Camarero S","year":"2022","unstructured":"Cabezas-Camarero S, P\u00e9rez-Alfayate R, Garc\u00eda-Barber\u00e1n V, et al.. Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome-associated glioma. Ther Adv Med Oncol. 2022, 14:1-16.","journal-title":"Ther Adv Med Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat M","year":"2020","unstructured":"Touat M, Li YY, Boynton AN, et al.. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020, 580:517-23. 10.1038\/s41586-020-2209-9","journal-title":"Nature"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/494629-exceptional-long-term-disease-stability-under-nivolumab-in-recurrent-high-grade-glioma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:10:52Z","timestamp":1781597452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/494629-exceptional-long-term-disease-stability-under-nivolumab-in-recurrent-high-grade-glioma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.110942","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}